# Validation of TERA Bio Station T101 of COVID-19 Tested Population.

> **NCT05088902** · — · UNKNOWN · sponsor: **Tera Group** · enrollment: 1000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** TERABio Ltd.

## Key facts

- **NCT ID:** NCT05088902
- **Lead sponsor:** Tera Group
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-22
- **Primary completion:** 2022-03-06
- **Final completion:** 2022-06-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088902, "Validation of TERA Bio Station T101 of COVID-19 Tested Population.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05088902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*